 Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of several TCRs for multiple HLAs across multiple targets; INDs filed for two MAGE-A1 TCRs TSC-204-A0201 and TSC-204-C0702 as well ... The post TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress appeared first on ForexTV... 